• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s R&D focuses on vaccines addressing high unmet medical needs.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A leading pure play vaccine company.

2015 Annual Business Report

— January 5, 2017

Valneva Announces a New Research License Agreement with MSD Animal Health for the Development of Vaccines in the EB66® Cell Line

Read more

— Stock information


— December 9, 2016
Valneva Receives FDA and European Approvals to Start Clinical Testing of Lyme Disease Vaccine Candidate

Read more
— Financial Calendar

February 23, 2017
Preliminary 2016 Results (Revenues, Cash)

March 23, 2017
2016 Financial Statements

See all dates

KOL event in N.Y. on Lyme disease



learn more
play video Valneva's CEO Thomas Lingelbach
comments on Group Strategy

– Upcoming conferences and fairs

Invest Securities BioMed Event
Paris, France
January 26, 2017

10th Kempen Life Sciences Conference
Amsterdam, NL
April 18-19, 2017

Please update your browser...